Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC.ALNY · Entity 3132 | Director · Chief Executive Officer | September 19, 2026 | September 22, 2026 |
| Moelis & CoMC · Entity 3898 | Director | November 14, 2018 | November 16, 2018 |
| Pacira BioSciences, Inc.PCRX · Entity 4928 | Director | June 08, 2022 | June 08, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ALNYLAM PHARMACEUTICALS, INC.
Report date September 19, 2026 · Filed September 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 95,802 |
Reported balance
After 2026-09-19 transaction · row 1
1 source rowRow 1 · 2026-09-19 · Grant · Acquired 107 · Balance 95,802 F1: On February 23, 2016, the People, Culture, and Compensation Committee of the issuer approved the issuance of shares of Company common stock having an aggregate value of USD $50,000 to each employee who completes 10 consecutive years of employment. The shares issued and reported here on Form 4, net of the minimum statutory tax liability, were issued to the reporting person in recognition of 10 years of continuous employment on September 19, 2026. |
| Common StockSEC Table I · non-derivative | Indirectby Managed Account | 407 |
Reported balance
Holding disclosure · report date 2026-09-19 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 407 F2: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program. |
Filing footnotes · ownership attribution and instrument terms
F1: On February 23, 2016, the People, Culture, and Compensation Committee of the issuer approved the issuance of shares of Company common stock having an aggregate value of USD $50,000 to each employee who completes 10 consecutive years of employment. The shares issued and reported here on Form 4, net of the minimum statutory tax liability, were issued to the reporting person in recognition of 10 years of continuous employment on September 19, 2026.
F2: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program.
Moelis & Co
Report date November 14, 2018 · Filed November 16, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| 2017 Annual Restricted Stock UnitsSEC Table I · non-derivative | Direct | 1,156.96 |
Reported balance
After 2018-11-14 transaction · row 1
1 source rowRow 1 · 2018-11-14 · Grant · Acquired 13.39 · Balance 1,156.96 F1: Each Initial Restricted Stock Unit (RSU) represents the right to receive one share of Class A common stock. F2: 2017 Annual RSUs were issued as dividend equivalents on holder's underlying Annual RSUs issued on July 1, 2017. The dividend equivalent Annual RSUs will vest concurrently with the vesting of the underlying Annual RSUs. |
| 2018 Annual Restricted Stock UnitsSEC Table I · non-derivative | Direct | 706.23 |
Reported balance
After 2018-11-14 transaction · row 2
1 source rowRow 2 · 2018-11-14 · Grant · Acquired 8.17 · Balance 706.23 F1: Each Initial Restricted Stock Unit (RSU) represents the right to receive one share of Class A common stock. F3: 2018 Annual RSUs were issued as dividend equivalents on holder's underlying Annual RSUs issued on July 2, 2018. The dividend equivalent Annual RSUs will vest concurrently with the vesting of the underlying Annual RSUs. |
| 2018 Elective Restricted Stock UnitsSEC Table I · non-derivative | Direct | 1,059.34 |
Reported balance
After 2018-11-14 transaction · row 3
1 source rowRow 3 · 2018-11-14 · Grant · Acquired 12.26 · Balance 1,059.34 F1: Each Initial Restricted Stock Unit (RSU) represents the right to receive one share of Class A common stock. F4: 2018 Elective RSUs were issued as dividend equivalents on holder's underlying Elective RSUs issued on July 2, 2018. The dividend equivalent Elective RSUs will vest concurrently with the vesting of the underlying Elective RSUs. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Initial Restricted Stock Unit (RSU) represents the right to receive one share of Class A common stock.
F2: 2017 Annual RSUs were issued as dividend equivalents on holder's underlying Annual RSUs issued on July 1, 2017. The dividend equivalent Annual RSUs will vest concurrently with the vesting of the underlying Annual RSUs.
F3: 2018 Annual RSUs were issued as dividend equivalents on holder's underlying Annual RSUs issued on July 2, 2018. The dividend equivalent Annual RSUs will vest concurrently with the vesting of the underlying Annual RSUs.
F4: 2018 Elective RSUs were issued as dividend equivalents on holder's underlying Elective RSUs issued on July 2, 2018. The dividend equivalent Elective RSUs will vest concurrently with the vesting of the underlying Elective RSUs.
Pacira BioSciences, Inc.
Report date June 08, 2022 · Filed June 08, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 13,247 |
Reported balance
After 2022-06-08 transaction · row 1
1 source rowRow 1 · 2022-06-08 · Grant · Acquired 1,160 · Balance 13,247 F1: Represents restricted stock units that vest on June 3, 2023, provided that the reporting person remains in continuous service with the issuer through the vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $59.39 · Expires 2032-06-08 | Direct | 8,225 |
Reported balance
After 2022-06-08 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-06-08 · Grant · Acquired 8,225 · Balance 8,225 |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units that vest on June 3, 2023, provided that the reporting person remains in continuous service with the issuer through the vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 19, 2026 Filed Sep 22, 2026 20:07 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantCommon Stock | 107 | $0.00 | $0.00 |
DisclosureSEC source: 0001178670-26-000065 · form4.xml · nonDerivative · entry 1 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 95,802 F1 · kind: On February 23, 2016, the People, Culture, and Compensation Committee of the issuer approved the issuance of shares of Company common stock having an aggregate value of USD $50,000 to each employee who completes 10 consecutive years of employment. The shares issued and reported here on Form 4, net of the minimum statutory tax liability, were issued to the reporting person in recognition of 10 years of continuous employment on September 19, 2026. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 21:13 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 265 | $325.67 | $86,302.55 |
DisclosureSEC source: 0001735276-26-000062 · edgardoc.xml · nonDerivative · entry 8 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 95,695 F1 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units. F9 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $325.40 to $326.21. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 21:13 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 345 | $324.88 | $112,083.60 |
DisclosureSEC source: 0001735276-26-000062 · edgardoc.xml · nonDerivative · entry 7 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 95,960 F1 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units. F8 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $324.39 to $325.38. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 21:13 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 973 | $323.84 | $315,096.32 |
DisclosureSEC source: 0001735276-26-000062 · edgardoc.xml · nonDerivative · entry 6 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 96,305 F1 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units. F7 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $323.38 to $324.35. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 21:13 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 444 | $323.01 | $143,416.44 |
DisclosureSEC source: 0001735276-26-000062 · edgardoc.xml · nonDerivative · entry 5 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 97,278 F1 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units. F6 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $322.36 to $323.36. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 21:13 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 368 | $321.82 | $118,429.76 |
DisclosureSEC source: 0001735276-26-000062 · edgardoc.xml · nonDerivative · entry 4 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 97,722 F1 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units. F5 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $321.34 to $322.31. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 21:13 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 274 | $320.81 | $87,901.94 |
DisclosureSEC source: 0001735276-26-000062 · edgardoc.xml · nonDerivative · entry 3 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 98,090 F1 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units. F4 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $320.33 to $321.33. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 21:13 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 129 | $320.01 | $41,281.29 |
DisclosureSEC source: 0001735276-26-000062 · edgardoc.xml · nonDerivative · entry 2 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 98,364 F1 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units. F3 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $319.28 to $320.28. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 21:13 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 135 | $319.03 | $43,069.05 |
DisclosureSEC source: 0001735276-26-000062 · edgardoc.xml · nonDerivative · entry 1 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 98,493 F1 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units. F2 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $318.27 to $319.27. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| March 02, 2026 Filed Mar 5, 2026 00:29 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantStock Price Performance Stock Unit · Derivative | 110,746 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001735276-26-000048 · edgardoc.xml · derivative · entry 14 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 110,746 Underlying: Common Stock · 110,746 shares Expires not disclosed F15 · derivative.exercise_date: Stock price performance unit award (PSU) granted pursuant to the Second Amended and Restated 2018 Stock Incentive Plan. The amount reported is the maximum number of PSUs that may be earned upon achievement of pre-set stock price thresholds. Subject to the terms and conditions of the PSU award agreement, the PSU vests on December 31, 2029 (Vesting Date) and between 50% and 200% of the target number of 55,373 PSUs may be earned if the highest average closing price that is achieved over a 30 consecutive trading period (Future Average Stock Price) in the six months preceding the vesting date (Measurement Period) meets or exceeds certain thresholds. If the Future Average Stock Price does not meet or exceed the baseline threshold price during the Measurement Period, no portion of the PSU will be earned, and all PSUs will be forfeited on the Vesting Date. F15 · derivative.expiration_date: Stock price performance unit award (PSU) granted pursuant to the Second Amended and Restated 2018 Stock Incentive Plan. The amount reported is the maximum number of PSUs that may be earned upon achievement of pre-set stock price thresholds. Subject to the terms and conditions of the PSU award agreement, the PSU vests on December 31, 2029 (Vesting Date) and between 50% and 200% of the target number of 55,373 PSUs may be earned if the highest average closing price that is achieved over a 30 consecutive trading period (Future Average Stock Price) in the six months preceding the vesting date (Measurement Period) meets or exceeds certain thresholds. If the Future Average Stock Price does not meet or exceed the baseline threshold price during the Measurement Period, no portion of the PSU will be earned, and all PSUs will be forfeited on the Vesting Date. F15 · derivative.underlying_shares: Stock price performance unit award (PSU) granted pursuant to the Second Amended and Restated 2018 Stock Incentive Plan. The amount reported is the maximum number of PSUs that may be earned upon achievement of pre-set stock price thresholds. Subject to the terms and conditions of the PSU award agreement, the PSU vests on December 31, 2029 (Vesting Date) and between 50% and 200% of the target number of 55,373 PSUs may be earned if the highest average closing price that is achieved over a 30 consecutive trading period (Future Average Stock Price) in the six months preceding the vesting date (Measurement Period) meets or exceeds certain thresholds. If the Future Average Stock Price does not meet or exceed the baseline threshold price during the Measurement Period, no portion of the PSU will be earned, and all PSUs will be forfeited on the Vesting Date. Read SEC document |
| March 02, 2026 Filed Mar 5, 2026 00:29 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantStock Option (right to buy) · Derivative | 30,425 | $0.00 Strike: $325.07 | $0.00 |
DisclosureSEC source: 0001735276-26-000048 · edgardoc.xml · derivative · entry 13 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,425 Underlying: Common Stock · 30,425 shares Expires 2036-03-02 F14 · derivative.exercise_date: The stock option vests as to 25% of the shares on the first anniversary of the grant date and the remaining shares vest in equal installments at the end of each successive three-month period thereafter until the fourth anniversary of the grant date, subject to the Reporting Persons continuous service with the Issuer as of each such vesting date. Read SEC document |
| March 02, 2026 Filed Mar 5, 2026 00:29 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 160 | $332.64 | $53,222.40 |
DisclosureSEC source: 0001735276-26-000048 · edgardoc.xml · nonDerivative · entry 11 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 98,628 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations. F12 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $332.34 to $332.24. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| March 02, 2026 Filed Mar 5, 2026 00:29 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 399 | $331.93 | $132,440.07 |
DisclosureSEC source: 0001735276-26-000048 · edgardoc.xml · nonDerivative · entry 10 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 98,788 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations. F11 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $331.32 to $332.31. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| March 02, 2026 Filed Mar 5, 2026 00:29 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 346 | $330.85 | $114,474.10 |
DisclosureSEC source: 0001735276-26-000048 · edgardoc.xml · nonDerivative · entry 9 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 99,187 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations. F10 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $330.30 to $331.30. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| March 02, 2026 Filed Mar 5, 2026 00:29 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 722 | $329.71 | $238,050.62 |
DisclosureSEC source: 0001735276-26-000048 · edgardoc.xml · nonDerivative · entry 8 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 99,533 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations. F9 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $329.29 to $330.29. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| March 02, 2026 Filed Mar 5, 2026 00:29 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 424 | $328.71 | $139,373.04 |
DisclosureSEC source: 0001735276-26-000048 · edgardoc.xml · nonDerivative · entry 7 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,255 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations. F8 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $328.28 to $329.26. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| March 02, 2026 Filed Mar 5, 2026 00:29 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 1,399 | $327.67 | $458,410.33 |
DisclosureSEC source: 0001735276-26-000048 · edgardoc.xml · nonDerivative · entry 6 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,679 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations. F7 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $327.24 to $328.24. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| March 02, 2026 Filed Mar 5, 2026 00:29 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 1,669 | $326.81 | $545,445.89 |
DisclosureSEC source: 0001735276-26-000048 · edgardoc.xml · nonDerivative · entry 5 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 102,078 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations. F6 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $326.23 to $327.23. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| March 02, 2026 Filed Mar 5, 2026 00:29 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 1,098 | $325.63 | $357,541.74 |
DisclosureSEC source: 0001735276-26-000048 · edgardoc.xml · nonDerivative · entry 4 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 103,747 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations. F5 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $325.21 to $326.21. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| March 02, 2026 Filed Mar 5, 2026 00:29 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 382 | $324.65 | $124,016.30 |
DisclosureSEC source: 0001735276-26-000048 · edgardoc.xml · nonDerivative · entry 3 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 104,845 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations. F4 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $324.20 to $325.20. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| March 02, 2026 Filed Mar 5, 2026 00:29 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 200 | $323.62 | $64,724.00 |
DisclosureSEC source: 0001735276-26-000048 · edgardoc.xml · nonDerivative · entry 2 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 105,227 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations. F3 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $323.16 to $324.15. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| March 02, 2026 Filed Mar 5, 2026 00:29 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantCommon Stock | 13,844 | $0.00 | $0.00 |
DisclosureSEC source: 0001735276-26-000048 · edgardoc.xml · nonDerivative · entry 1 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 105,427 F1 · shares: These shares are represented by restricted stock units (RSUs) granted under the Second Amended and Restated 2018 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock. The RSUs will vest over a three-year period, with one third vesting on each of the first, second and third anniversaries of the grant date, subject to the Reporting Persons continuous service with the Issuer as of each such vesting date. Read SEC document |
| February 27, 2026 Filed Mar 2, 2026 21:10 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionRestricted Stock Units · Derivative | 5,921 | $0.00 | $0.00 |
DisclosureSEC source: 0001735276-26-000041 · edgardoc.xml · derivative · entry 3 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,921 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: These shares are represented by restricted stock units (RSUs) granted under the Amended and Restated 2018 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock. F3 · derivative.exercise_date: On February 27, 2023, the reporting person was granted 17,763 restricted stock units that vest ratably on each of the first, second and third anniversaries of the Grant Date. On February 27, 2026, the third and final tranche of restricted stock units from the February 27, 2023 grant vested and was released, as reported on this Form 4. F4 · derivative.expiration_date: The restricted stock units vest ratably in three installments, with one third vesting on each of the first, second and third anniversaries of the grant date. Read SEC document |
| February 27, 2026 Filed Mar 2, 2026 21:10 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionCommon Stock | 5,921 | $0.00 | $0.00 |
DisclosureSEC source: 0001735276-26-000041 · edgardoc.xml · nonDerivative · entry 1 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 91,583 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 13, 2026 Filed Feb 18, 2026 00:27 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 6,958 | $310.08 | $2,157,542.21 |
DisclosureSEC source: 0001735276-26-000028 · edgardoc.xml · nonDerivative · entry 2 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,662 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations. F3 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $302.55 to $314.60. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 12, 2026 Filed Feb 18, 2026 00:27 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantCommon Stock | 14,209 | $0.00 | $0.00 |
DisclosureSEC source: 0001735276-26-000028 · edgardoc.xml · nonDerivative · entry 1 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 92,620 F1 · kind: On February 27, 2023, the reporting person was granted a performance-based stock unit (PSU) under the 2018 Stock Incentive Plan. The shares subject to the PSU vest based on the achievement of three specified performance measures. The shares reported were issued to the reporting person upon vesting of forty (40) percent of the shares subject to the PSU based on the issuer publicly reporting the achievement of non-GAAP operating income for fiscal year 2025 on February 12, 2026, as determined by the People, Culture and Compensation Committee of the Issuer Board of Directors. Read SEC document |
| January 12, 2026 Filed Jan 14, 2026 21:23 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 94 | $377.82 | $35,515.08 |
DisclosureSEC source: 0001735276-26-000014 · edgardoc.xml · nonDerivative · entry 22 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,411 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations. Read SEC document |
| January 12, 2026 Filed Jan 14, 2026 21:23 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 118 | $375.65 | $44,326.70 |
DisclosureSEC source: 0001735276-26-000014 · edgardoc.xml · nonDerivative · entry 21 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,505 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations. Read SEC document |
| January 12, 2026 Filed Jan 14, 2026 21:23 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 88 | $374.44 | $32,950.72 |
DisclosureSEC source: 0001735276-26-000014 · edgardoc.xml · nonDerivative · entry 20 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,623 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations. F21 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $374.08 to $374.89. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| January 12, 2026 Filed Jan 14, 2026 21:23 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 21 | $372.46 | $7,821.66 |
DisclosureSEC source: 0001735276-26-000014 · edgardoc.xml · nonDerivative · entry 19 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,711 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations. F20 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $372.35 to $372.50. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| January 12, 2026 Filed Jan 14, 2026 21:23 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 118 | $370.87 | $43,762.66 |
DisclosureSEC source: 0001735276-26-000014 · edgardoc.xml · nonDerivative · entry 18 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,732 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations. F19 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $370.43 to $371.23. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| January 12, 2026 Filed Jan 14, 2026 21:23 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 253 | $369.48 | $93,478.44 |
DisclosureSEC source: 0001735276-26-000014 · edgardoc.xml · nonDerivative · entry 17 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,850 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations. F18 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $369.13 to $369.93. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| January 12, 2026 Filed Jan 14, 2026 21:23 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 584 | $368.62 | $215,274.08 |
DisclosureSEC source: 0001735276-26-000014 · edgardoc.xml · nonDerivative · entry 16 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,103 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations. F17 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $368.09 to $369.08. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| January 12, 2026 Filed Jan 14, 2026 21:23 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 261 | $367.40 | $95,891.40 |
DisclosureSEC source: 0001735276-26-000014 · edgardoc.xml · nonDerivative · entry 15 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,687 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations. F16 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $367.04 to $368.00. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| January 12, 2026 Filed Jan 14, 2026 21:23 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 316 | $366.41 | $115,785.56 |
DisclosureSEC source: 0001735276-26-000014 · edgardoc.xml · nonDerivative · entry 14 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,948 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations. F15 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $366.03 to $366.96. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| January 12, 2026 Filed Jan 14, 2026 21:23 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 1,395 | $365.56 | $509,956.20 |
DisclosureSEC source: 0001735276-26-000014 · edgardoc.xml · nonDerivative · entry 13 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,264 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations. F14 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $365.01 to $366.01. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| January 12, 2026 Filed Jan 14, 2026 21:23 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 1,259 | $364.83 | $459,320.97 |
DisclosureSEC source: 0001735276-26-000014 · edgardoc.xml · nonDerivative · entry 12 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,659 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations. F13 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $364.00 to $365.00. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| January 12, 2026 Filed Jan 14, 2026 21:23 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 301 | $363.55 | $109,428.55 |
DisclosureSEC source: 0001735276-26-000014 · edgardoc.xml · nonDerivative · entry 11 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 82,918 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations. F12 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $362.99 to $363.99. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| January 12, 2026 Filed Jan 14, 2026 21:23 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 464 | $362.38 | $168,144.32 |
DisclosureSEC source: 0001735276-26-000014 · edgardoc.xml · nonDerivative · entry 10 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,219 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations. F11 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $361.93 to $362.92. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| January 12, 2026 Filed Jan 14, 2026 21:23 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 624 | $361.45 | $225,544.80 |
DisclosureSEC source: 0001735276-26-000014 · edgardoc.xml · nonDerivative · entry 9 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,683 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations. F10 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $360.90 to $361.89. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| January 12, 2026 Filed Jan 14, 2026 21:23 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 980 | $360.22 | $353,015.60 |
DisclosureSEC source: 0001735276-26-000014 · edgardoc.xml · nonDerivative · entry 8 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 84,307 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations. F9 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $359.79 to $360.79. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| January 12, 2026 Filed Jan 14, 2026 21:23 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 537 | $359.14 | $192,858.18 |
DisclosureSEC source: 0001735276-26-000014 · edgardoc.xml · nonDerivative · entry 7 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,287 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations. F8 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $358.69 to $359.66. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| January 12, 2026 Filed Jan 14, 2026 21:23 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 778 | $358.18 | $278,664.04 |
DisclosureSEC source: 0001735276-26-000014 · edgardoc.xml · nonDerivative · entry 6 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,824 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations. F7 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $357.68 to $358.68. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| January 12, 2026 Filed Jan 14, 2026 21:23 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 607 | $357.17 | $216,802.19 |
DisclosureSEC source: 0001735276-26-000014 · edgardoc.xml · nonDerivative · entry 5 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 86,602 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations. F6 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $356.63 to $357.63. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| January 12, 2026 Filed Jan 14, 2026 21:23 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 263 | $356.09 | $93,651.67 |
DisclosureSEC source: 0001735276-26-000014 · edgardoc.xml · nonDerivative · entry 4 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 87,209 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations. F5 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $356.62 to $356.61. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| January 12, 2026 Filed Jan 14, 2026 21:23 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 269 | $355.16 | $95,538.04 |
DisclosureSEC source: 0001735276-26-000014 · edgardoc.xml · nonDerivative · entry 3 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 87,472 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations. F4 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $354.54 to $355.53. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| January 12, 2026 Filed Jan 14, 2026 21:23 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 247 | $353.95 | $87,425.65 |
DisclosureSEC source: 0001735276-26-000014 · edgardoc.xml · nonDerivative · entry 2 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 87,741 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations. F3 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $353.53 to $354.41. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| January 11, 2026 Filed Jan 14, 2026 21:23 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantCommon Stock | 19,003 | $0.00 | $0.00 |
DisclosureSEC source: 0001735276-26-000014 · edgardoc.xml · nonDerivative · entry 1 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 87,988 F1 · kind: On March 1, 2024, the reporting person was granted a performance-based stock unit (PSU) under the 2018 Stock Incentive Plan. The shares subject to the PSU vest based on the achievement of three specified performance measures. The shares reported were issued to the reporting person upon vesting of forty (40) percent of the shares subject to the PSU based on the issuer publicly reporting $2.5 billion in annual net product revenue in accordance with GAAP, as determined by the People, Culture and Compensation Committee of the Issuer Board of Directors on January 11, 2026. Read SEC document |
| November 26, 2025 Filed Dec 1, 2025 21:10 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionStock Option (right to buy) · Derivative | 659 | $0.00 Strike: $151.59 | $0.00 |
DisclosureSEC source: 0001735276-25-000125 · edgardoc.xml · derivative · entry 10 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,141 Underlying: Common Stock · 659 shares Expires 2031-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: This stock option was fully vested and exercisable as of February 24, 2025. Read SEC document |
| November 26, 2025 Filed Dec 1, 2025 21:10 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionStock Option (right to buy) · Derivative | 839 | $0.00 Strike: $119.13 | $0.00 |
DisclosureSEC source: 0001735276-25-000125 · edgardoc.xml · derivative · entry 9 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 839 shares Expires 2028-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This stock option was fully vested and exercisable as of December 1, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.